There is widespread optimism that the single-use bioreactors market is likely to continue its double digit growth in the future. The concept of “single-use technology”, which started in 1970s with the use of vials and pipettes, has emerged rapidly over the last decade. Today, this term surrounds a wide range of primarily plastic disposable technologies that are suitable for a wide variety of scales, from upscale bioprocessing to final formulation and filling. These can be found in various manufacturing processes and a number of important applications.
A major advantage of single-use bioreactors is that they do not require cleaning or sterilisation. The bags involved in the process can be disposed and replaced by new bags. This lowers the chances of cross-contamination, making them more efficient. Compared to conventional stainless steel bioreactors, single-use bioreactors don’t require an extensive piping infrastructure and / or systems to support sterilisation in place (SIP) and cleaning in place (CIP) requirements. This saves a lot of time and upfront capital investment, making single-use bioreactors a preferred option for pharma / contract manufacturers worldwide.
The technology is gradually penetrating mainstream commercial manufacturing in the biopharmaceuticals industry. The growth of single-use bioreactors is evident by the wide range of equipment sizes available in the market today. Many companies have already transitioned from conventional bioreactors to single use bioreactors; others have firmed up their plans to migrate to single-use technology in multiple phases.
1. Single-use bioreactors are already being deployed for high density cell culture applications (monoclonal antibodies, recombinant proteins, vaccines etc.); newer application areas being researched include stem cells and personalised medicine.
2. We identified 17 manufacturers offering around 80-90 models of single-use bioreactors with working volumes ranging from as low as few millilitres to up to 2000L.
3. Manufacturing collaborations and acquisitions are rapidly changing the landscape; amongst the 50 odd partnerships we looked at, around 25% were manufacturing collaborations and an additional 25% were mergers / acquisitions.
4. Quite recently, many start-ups have sprung up; examples include CerCell, PBS Biotech, Cellexus Limited; these start-ups have launched single-use bioreactors with innovative features and are likely to play an increasingly important role in the future.
5. The overall industry could grow close to USD 1 billion in a few years’ time; however, this will be driven to a certain extent by the overall growth of the biopharmaceuticals’ market. Emergence of new technologies is likely to provide the necessary impetus to fuel future growth.
SCOPE OF THE REPORT
The ‘Single-use Bioreactors Market, 2014 - 2024’ report provides an extensive study of this industry, specifically focusing on all the companies manufacturing single-use bioreactors, their applications and the likely future evolution. Single-use bioreactors have tremendous potential: they require less space for production, one-third time for installation and, most importantly, offer a better product yield than the conventional stainless steel bioreactors. The report covers various aspects impacting the industry, such as, technological progress, evolving product portfolios, key challenges, industry partnerships and the likely future roadmap.
The base year for the report is 2013. The report provides multiple forecast scenarios for the period 2014 - 2024. These scenarios are based on a number of parameters, such as, the future growth of overall biopharmaceuticals industry and likely adoption of single-use technology vis-à-vis stainless steel bioreactors. Amongst other elements, we have discussed the key drivers behind the likely growth of single-use bioreactors market and identified avenues of growth for the future. One of the key objectives of the report is to provide a holistic market landscape of single-use bioreactors commercially available; this is presented in detail in various sections of the report.
Most of the data presented in this report has been gathered by secondary research. We have also conducted interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will shape up across different regions and drug segments. Where possible, the available data has been checked for accuracy from multiple sources of information.
The secondary sources of information include
1. Annual reports
2. Investor presentations
3. SEC filings
4. Industry databases
5. News releases from company websites
6. Government policy documents
7. Other analysts’ opinion reports
While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
Chapter 2 provides an executive summary of the insights captured in our research. The summary offers a high level view on where the single-use bioreactors market is headed in the mid-long term.
Chapter 3 provides a general introduction to single-use bioreactors. We have discussed, in detail, the origins of single-use bioreactors and recent developments which have shaped the industry so far. The chapter also elaborates on the current and future applications, and the challenges which have to be overcome before wider adoption of the technology takes place.
Chapter 4 provides an overview of the single-use bioreactors market with respect to the available technologies and companies active in the field. The analysis also identifies key industry partnerships which have recently taken place and the key drivers which are likely to determine the future growth.
Chapter 5 offers a comprehensive review of the major single-use bioreactors which have been made available by leading companies in the market. We present profiles of ten such bioreactors including their key features, usage mechanism, applications, recent partnerships and competitive landscape.
Chapter 6 presents a scenario based approach to identify the future evolution of the industry. Given the uncertainty surrounding the adoption rates, we have done a multivariate sensitivity analysis to present four different tracks of industry’s evolution.
Chapter 7 provides our analysis of the strengths, weaknesses, opportunities and threats in the single-use bioreactors market, capturing the key elements likely to influence future growth.
Chapter 8 is a collection of transcripts of interviews conducted during the course of this study.
Chapter 9 summarises the overall report. In this chapter, we provide a recap of the key takeaways and our independent opinion based on the research and analysis described in previous chapters.
Chapters 10 and 11 are appendices, which provide the list of companies and tabulated data for all the figures presented in the report.
LIST OF COMPANIES AND ORGANISATIONS
The following companies and organisations have been mentioned in the report.
6. ATMI Life Sciences
7. Avid Bioservices
8. Bayer Technology Services
11. Boehringer Ingelheim
13. Broadley James
15. Catalent Pharma Solutions
16. Cell Technology Group, School of Biotechnology, Royal Institute of Technology, KTH.
17. Cellexus Limited
18. CELLution Biotech
21. Charter Medical
22. CMC Biologics
23. Cobra Biologics
24. Colder Products Co.
25. Cytovance Biologics
27. Department of Systems biology, Danish Technical university (DTU)
28. DMT GmbH
29. Dync B.V.
30. Electrospinning Company
33. ExpreS2ion Biotechnologies
35. Fujifilm Diosynth Biotechnologies
36. G & G Technologies
37. Gallus Biologics
38. GE Healthcare Life Sciences
43. Infors HT
44. Integra Biosciences
45. Integrated Product Services
46. Integrity CMI
48. KBI BioPharma
49. Kuhner shaker
50. Kungliga Tekniska Högskolan(Stockholm)
51. Laureate Pharma
54. Meissner Products
55. Merck KGaA
56. Mibelle Biochemistry
57. Millipore Corporation
60. New Brunswick
61. Novartis Pharma
62. Novavax Inc.
63. Pall Corporation
64. PBS Biotech
66. Pierre Guerin
67. Polestar Technologies
68. Presens Precision Sensing GmbH
69. Pristine Bioproduction
72. Refine Technology
73. Roche Diagnostics GmbH
74. SAFC Biosciences
76. Sartorius-Stedim Biosystems
77. School of Life Sciences and Facility Management (IBT), Switzerland
79. Scrum Inc.
81. Single-use Processing systems
82. Solaris Group
83. Stobbe Tech A/S
84. Sudpack Medica AG
87. TAP Biosystems
88. Tarom Applied Technologies
89. Technical University, Berlin
90. Thermo Fisher Scientific
91. United Therapeutics
92. Wave Biotech AG
93. Wave Biotech LLC
94. WuXiPharma Tech